{"entity":{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","aka":["Aprea Therapeutics, Inc.","Aprea"],"tldr":"Aprea developed eprenetapopt, a drug meant to restore the function of mutant p53, which failed its phase 3 trial in TP53-mutant myelodysplastic syndromes in 2020; the company now works on ATR and WEE1 inhibitors.","summary":"Aprea Therapeutics, founded in Stockholm and now based in Doylestown, Pennsylvania and listed on Nasdaq, developed eprenetapopt (APR-246), a small molecule intended to refold mutant p53 into its active form. Combined with azacitidine it produced encouraging phase 2 remissions in TP53-mutant myelodysplastic syndromes, but the phase 3 trial missed its complete remission endpoint in December 2020. The company pivoted to DNA damage response drugs, including the ATR inhibitor ATRN-119 and a WEE1 inhibitor. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://aprea.com"},{"label":"ClinicalTrials.gov: trials led by Aprea Therapeutics","url":"https://clinicaltrials.gov/search?lead=Aprea%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["mds","aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["tp53","atr"],"drugs":["eprenetapopt"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Doylestown, PA","country":"US","companyType":"biotech","website":"https://aprea.com","stage":"public","investors":[],"funding":[]},"route":"/companies/aprea-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"drug":[{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/"}]}}